Ostia Sciences Inc.

Healthcare
Toronto, Ontario, Canada
contact@ostia-sciences.com
Ostia Sciences Inc.
Ostia Sciences Inc.

$910,000.00

Funded Of $1,400,000.00 Goal
65% Raised
Accredited Investor Offer. Structure
47 Days Days Left
$50,000.00 Min. investment
$1,400,000.00 Max. investment
N/A Minimum Raise
$1,400,000 Maximum Raise

Offering Description

Offering Terms

NOTE: You will need your Bank Account Number, Transit Number, and Institution Number to Invest.

This Offering is NOT TFSA/RRSP Eligible.

Pre-money valuation (before investment received): $10,000,000

Minimum Raise: N/A

Max Raise: $1,400,000 for Common Shares at $1 per Common Share.

Minimum investment amount: $50,000.00

Shares Outstanding: 1,000,000 Common Shares

Securities offered: Common Shares (Voting)

Please see Articles on Incorporation, Term Sheet, and the Shareholder's Agreement for full details of rights associated with the Shares.  You must create an account on Equivesto to view attached documents.

Forward Looking Statements Disclosure

The information contained within this offering page and related presentations constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) sources, availability, and the use of proceeds from third-party financing for the Company’s projects; (iii) the expected development of the Company’s business, projects, and partnerships; (iv) execution of the Company’s vision and growth strategy; and (v) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. 

These statements should not be taken as guarantees of future performance, and undue reliance should not be placed upon them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. 

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. 

Please review the Issuer’s Business and Risks sections of the Offering Document or Offering Memorandum if available for full explanations of the material factors, assumptions used and risks. 

The forward-looking statements have been approved by management as of the launch date of this offering.

02/28/2024
Project launched

07/08/2024

Ostia Shareholder's Agreement Update

Ostia Sciences, alongside it's two lead Angel investors, has updated it's shareholder's agreement.  This agreement includes greater protections for investors, but much of the core material remains the same as the existing agreement.  A copy of the updated agreement is provided here and on the offering page for your review. 

All currently participating investors will automatically be added to the new shareholder's agreement via the Joinder Agreement already signed when making your investment, so if you are comfortable with the updated agreement, no action is required on your end.

If you would like to rescind your investment as a result of this updated agreement, please respond to alexander.morsink@equivesto.com by 5pm ET on Friday July 12, 2024.  

Read More

07/12/2024

Ostia Sciences First Closing July 12, 2024

Ostia Sciences has declared it's first closing as of July 12, 2024.  Funds invested up until that date will be released from Equivesto' trust account and provided to Ostia Sciences.  Those funds will be deployed by Ostia as per the outlined Use of Funds, including finalizing the acquisition of the patent from the University of Toronto and filing the official patent application documentation.  

Building on the success of the offering to date, Ostia has extended the offering raise target to $1,400,000.  There will be a second close expected for August 31, 2024.  There is no change in investment terms between the first and second closing.  

Read More

FAQs

No Q&A have been posted for this campaign yet. Ask the project creator directly.